Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany

Objective Due to the growing complexity in monitoring and treatment of many disorders, disease-specific care and research networks offer patients certified healthcare. However, the networks’ ability to provide health services close to patients’ homes usually remains vague. Digital Health Technologies (DHTs) help to provide better care, especially if implemented in a targeted manner in regions undersupplied by specialised networks. Therefore, we used a car travel time-based isochrone approach to identify care gaps using the example of the neuroinflammation-focused German healthcare and research networks for multiple sclerosis (MS), myasthenia gravis (MG), myositis and immune-mediated neuropathy. Methods Excellence centres were mapped, and isochrones for 30, 60, 90 and 120 minutes were calculated. The resulting geometric figures were aggregated and used to mask the global human settlement population grid 2019 to estimate German inhabitants that can reach centres within the given periods. Results While 96.48% of Germans can drive to an MS-focused centre within one hour, coverage is lower for the rare disease networks for MG (48.3%), myositis (43.1%) and immune-mediated neuropathy (56.7%). Within 120 minutes, more than 80% of Germans can reach a centre of any network. Besides the generally worse covered rural regions such as North-Eastern Germany, the rare disease networks also show network-specific regional underrepresentation. Conclusion An isochrone-based approach helps identify regions where specialised care is hard to reach, which might be especially troublesome in the case of an often disabled patient collective. Patient care could be improved by focusing deployments of disease-specific DHTs on these areas.

[1]  H. Hartung,et al.  Thinking outside the box: non-canonical targets in multiple sclerosis , 2022, Nature Reviews Drug Discovery.

[2]  King Chung Ho,et al.  Virtual exam for Parkinson’s disease enables frequent and reliable remote measurements of motor function , 2022, npj Digital Medicine.

[3]  H. Hartung,et al.  Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapies. , 2022, Multiple sclerosis and related disorders.

[4]  D. Foell,et al.  Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients , 2022, Journal of neuroinflammation.

[5]  Bakul Patel,et al.  Digital biomarkers: Convergence of digital health technologies and biomarkers , 2022, npj Digital Medicine.

[6]  Jonas Jacobi,et al.  Burden of disease in myasthenia gravis: taking the patient’s perspective , 2021, Journal of Neurology.

[7]  T. Ziemssen,et al.  Digital Biomarkers in Multiple Sclerosis , 2021, Brain sciences.

[8]  L. Leocani,et al.  Myasthenia gravis and telemedicine: a lesson from COVID-19 pandemic , 2021, Neurological Sciences.

[9]  Jeff Reback,et al.  pandas-dev/pandas: Pandas 1.2.4 , 2021 .

[10]  P. Urban,et al.  A Sum Score to Define Therapy-Refractory Myasthenia Gravis: A German Consensus , 2021, Journal of central nervous system disease.

[11]  T. Friede,et al.  [Multiple sclerosis in Germany: updated analysis of the German MS Registry 2014-2018]. , 2020, Fortschritte der Neurologie-Psychiatrie.

[12]  Elzbieta Bielecka,et al.  GHS-POP Accuracy Assessment: Poland and Portugal Case Study , 2020, Remote. Sens..

[13]  X. Montalban,et al.  Adherence and Satisfaction of Smartphone- and Smartwatch-Based Remote Active Testing and Passive Monitoring in People With Multiple Sclerosis: Nonrandomized Interventional Feasibility Study , 2019, Journal of medical Internet research.

[14]  S. Freire,et al.  GHS-POP R2019A - GHS population grid multitemporal (1975-1990-2000-2015) , 2019 .

[15]  R. Valdez,et al.  A compilation of national plans, policies and government actions for rare diseases in 23 countries. , 2018, Intractable & rare diseases research.

[16]  M. Puhan,et al.  Factors associated with time from first-symptoms to diagnosis and treatment initiation of Multiple Sclerosis in Switzerland , 2018, Multiple sclerosis journal - experimental, translational and clinical.

[17]  Peter Feys,et al.  The Use of Digital and Remote Communication Technologies as a Tool for Multiple Sclerosis Management: Narrative Review , 2018, JMIR rehabilitation and assistive technologies.

[18]  R. Gold,et al.  Neuroimmunological Registries in Germany , 2018, Neurology International Open.

[19]  S. Neumeier Regionale Erreichbarkeit von ausgewählten Fachärzten, Apotheken, ambulanten Pflegediensten und weiteren ausgewählten Medizindienstleistungen in Deutschland: Abschätzung auf Basis des Thünen-Erreichbarkeitsmodells , 2017 .

[20]  G. Kobelt,et al.  New insights into the burden and costs of multiple sclerosis in Europe: Results for Germany , 2017, Multiple sclerosis.

[21]  T. Farragher,et al.  Are differences in travel time or distance to healthcare for adults in global north countries associated with an impact on health outcomes? A systematic review , 2016, BMJ Open.

[22]  Juan Wisnivesky,et al.  Geographic accessibility to clinical trials for advanced cancer in the United States. , 2015, JAMA internal medicine.

[23]  M. Fritzler,et al.  Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. , 2014, Autoimmunity reviews.

[24]  J. Kugler,et al.  Quality of life and life circumstances in German myasthenia gravis patients , 2010, Health and quality of life outcomes.

[25]  Pascal Neis,et al.  Extending the OGC OpenLS Route Service to 3D for an interoperable realisation of 3D focus maps with landmarks , 2008, J. Locat. Based Serv..

[26]  OUP accepted manuscript , 2021, Brain.

[27]  Paul Roderick,et al.  International Journal of Health Geographics Open Access Distance, Rurality and the Need for Care: Access to Health Services in South West England , 2022 .